ReviewPneumonia (Nathan Qld.)2016
How and when to use common biomarkers in community-acquired pneumonia.
Review in Pneumonia (Nathan Qld.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Interleukins in community-acquired pneumonia: from biomarkers to precision medicine.Frontiers in immunology · 2026Review
- Immune monitoring, immune phenotyping, and precision intervention in severe pneumonia: current evidence and translational challenges.Frontiers in immunology · 2026Review
- Biomarkers troponin and procalcitonin in addition to CRB-65 enhance risk stratification in patients with community-acquired pneumonia.ERJ open research · 2024Article
- Diagnostic test accuracy of cellular analysis of bronchoalveolar lavage fluid in distinguishing pulmonary infectious and non-infectious diseases in patients with pulmonary shadow.Frontiers in medicine · 2024Article
- Evaluation of Plasma Lipocalin-2 as a Predictor of Etiology and Severity in Adult Patients with Community-Acquired Pneumonia.Microorganisms · 2023Article
- Cellular analysis and metagenomic next-generation sequencing of bronchoalveolar lavage fluid in the distinction between pulmonary non-infectious and infectious disease.Frontiers in cellular and infection microbiology · 2022Article
- Corticosteroids in Community-Acquired Pneumonia: A Review of Current Literature.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2021Review
- Calprotectin: An Ignored Biomarker of Neutrophilia in Pediatric Respiratory Diseases.Children (Basel, Switzerland) · 2021Review
- Diagnostic markers for community-acquired pneumonia.Annals of translational medicine · 2020Review
- Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: The role of inflammatory biomarkers.World journal of critical care medicine · 2019Review
- Hot topics and current controversies in community-acquired pneumonia.Breathe (Sheffield, England) · 2019Review
- Evaluation of dynamic thiol/disulfide redox state in community-acquired pneumonia.Saudi medical journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Community-acquired pneumonia (CAP) is a leading cause of death in both the developed and developing world. The very young and elderly are especially vulnerable. Even with appropriate early antibiotics we still have not improved the outcomes in these patients since the 1950s, with 30-day case fatality rates of between 10-12%. Interventions to improve outcomes include immunomodulatory agents such as macrolides and corticosteroids. Treating doctors identify CAP patients who are likely to have poor outcomes by using severity scores such as the pneumonia severity index and CURB-65, which allows these patients to be placed in ICU settings from the start of the admission. Another novel way to identify these patients is with the use of biomarkers. This review illustrates how various biomarkers have been shown to predict mortality, complications and response to treatment in CAP patients. The evidence using either procalcitonin or C-reactive protein to demonstrate response to treatment and hence that the antibiotics chosen are appropriate can play an important role in antibiotic stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.